Darbepoetin Alfa
Brand Names: Aranesp
Methodology & AI Transparency ⓘ
Darbepoetin Alfa Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 100 ug/mL Solution and 40 ug/mL Solution and manufactured/labeled by Amgen, Inc (NDC 55513-005, 55513-003), Darbepoetin Alfa operates within intravenous-route erythropoiesis-stimulating agent treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: 76% patient "Worth It" rating across 7 anonymous logs for Darbepoetin Alfa (RxNorm RXN-55513005-2374).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($446.5774/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Darbepoetin Alfa): nausea (7.9%), headache (7.9%), dizziness (5.5%).
Ask our AI Specialists anything about Darbepoetin Alfa
Darbepoetin Alfa Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 100 ug/mL Solution and 40 ug/mL Solution and manufactured/labeled by Amgen, Inc (NDC 55513-005, 55513-003), Darbepoetin Alfa operates within intravenous-route erythropoiesis-stimulating agent treatment algorithms requiring prescription authorization.
Delivered via 100 ug/mL Solution and 40 ug/mL Solution (intravenous-route; NDC 55513-005, 55513-003), Darbepoetin Alfa mediates erythropoiesis-stimulating agent physiological effects manufactured/labeled by Amgen, Inc with dose-dependent receptor occupancy and systemic clearance.
Following administration (100 ug/mL Solution), Darbepoetin Alfa achieves Systemic oral bioavailability of roughly 47%–59% following first-pass transit bioavailability and initial pharmacodynamic onset within 1–2 hrs (peak cmax) for darbepoetin alfa onset, governed by a Biphasic clearance with 11–19 hr terminal t½ under Darbepoetin Alfa maintenance terminal half-life through hepatic enzymatic processing and renal clearance proportional to creatinine clearance (darbepoetin alfa).
Before initiating Darbepoetin Alfa at 100 ug/mL Solution, clinical safety checklists rule out prior anaphylaxis, angioedema, or severe hypersensitivity to darbepoetin alfa or darbepoetin alfa excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 darbepoetin alfa spl. Logged tolerability patterns center on nausea (7.9% of reports), headache (7.9% of reports), fatigue (5.6% of reports).
Avoid overlapping erythropoiesis-stimulating agent prescriptions alongside Darbepoetin Alfa to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Darbepoetin Alfa; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Darbepoetin Alfa or Darbepoetin Alfa excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Darbepoetin Alfa SPL
Logged Side-Effect Incidence (7 Reports)
Darbepoetin Alfa Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Darbepoetin Alfa)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the: What a 7,373-Participant Study Found In patients randomized to vadadustat versus darbepoetin alfa, rates of TEAEs (88.9% vs. American journal of nephrology • 2022-01-15 • Phase III Randomized Trial | N = 7,373 | 90/100 | PMID 36450264 ↗ |
| Can This Approach Help? Inside the Latest Research on Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia The relationship between roxadustat doses and end of treatment (EoT) hs-CRP was not significant (estimated slope, -0.494; P = .814); a trend toward increased DA doses was observed with increasing EoT hs-CRP (estimated slope,. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2021-10-15 • Phase III Randomized Trial | N = 151 | 88/100 | PMID 33200512 ↗ |
| New Insights on Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A: What a 588-Participant Study Found Desidustat is non-inferior to darbepoetin in the treatment of anemia due to non-dialysis dependent CKD and it is well-tolerated. American journal of nephrology • 2022-01-15 • Phase III Randomized Trial | N = 588 | 87/100 | PMID 35462372 ↗ |
| New Insights on Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in: What a 756-Participant Study Found These findings indicate no evidence of difference in incidence of red blood cell transfusion for a titration-dose strategy versus a fixed-dose strategy for darbepoetin. Journal of the American Society of Nephrology : JASN • 2021-02-15 • Phase III Randomized Trial | N = 756 | 87/100 | PMID 33288629 ↗ |
| Factors Affecting Doses of Roxadustat vs. Darbepoetin Alfa: Which Works Better for Anemia in Nondialysis Patients? Two hundred and sixty-two patients were randomized to either the roxadustat or DA comparative group and received treatment (roxadustat, n = 131; DA, n = 131). American journal of nephrology • 2021-01-15 • Phase III Randomized Trial | N = 131 | 82/100 | PMID 34628408 ↗ |
Darbepoetin Alfa Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $446.5774/unit (~$13397.32/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Darbepoetin Alfa Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Darbepoetin Alfa RxNorm Concept ID | RXN-55513005-2374 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $446.5774 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Darbepoetin Alfa Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Darbepoetin Alfa: FDA labeling (2026-07-01, NDC 55513-005), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Darbepoetin Alfa community threads and patient logs by age, biological sex, dosage, and treatment duration.